Filing Details
- Accession Number:
- 0001104659-18-042302
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2018-06-26 16:47:53
- Reporting Period:
- 2018-06-25
- Accepted Time:
- 2018-06-26 16:47:53
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1674365 | Aptinyx Inc. | APTX | Pharmaceutical Preparations (2834) | 474626057 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1741606 | R. Joseph Moskal | C/O Aptinyx Inc. 909 Davis Street, Suite 600 Evanston IL 60201 | Chief Scientific Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2018-06-25 | 8,464 | $0.00 | 359,063 | No | 4 | C | Direct | |
| Common Stock | Acquisiton | 2018-06-25 | 9,673 | $0.00 | 368,736 | No | 4 | C | Direct | |
| Common Stock | Acquisiton | 2018-06-25 | 6,552 | $0.00 | 375,288 | No | 4 | C | Direct | |
| Common Stock | Acquisiton | 2018-06-25 | 3,000 | $16.00 | 378,288 | No | 4 | P | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | C | Direct | |
| No | 4 | C | Direct | |
| No | 4 | C | Direct | |
| No | 4 | P | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Series A-1 Convertible Preferred Stock | Disposition | 2018-06-25 | 233,496 | $0.00 | 8,464 | $0.00 |
| Common Stock | Series A-2 Convertible Preferred Stock | Disposition | 2018-06-25 | 266,851 | $0.00 | 9,673 | $0.00 |
| Common Stock | Series B Convertible Preferred Stock | Disposition | 2018-06-25 | 180,734 | $0.00 | 6,552 | $0.00 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 0 | No | 4 | C | Direct | ||
| 0 | No | 4 | C | Direct | ||
| 0 | No | 4 | C | Direct |
Footnotes
- Each share of Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 27.58621-for-one basis immediately prior to the closing of the Issuer's initial public offering without payment or consideration. The shares of Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock had no expiration date.
- On June 25, 2018, the Reporting Person purchased 3,000 shares of common stock of the Issuer at a price of $16.00 per share pursuant to an underwritten public offering.
Billionaire Hedge Funds
